Histone deacetylase inhibitors in castration-resistant prostate cancer: Molecular mechanism of action and recent clinical trials

Dharam Kaushik, Vishal Vashistha, Sudhir Isharwal, Soud A. Sediqe, Ming Fong Lin

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Historically, androgen-deprivation therapy has been the cornerstone for treatment of metastatic prostate cancer. Unfortunately, nearly majority patients with prostate cancer transition to the refractory state of castration-resistant prostate cancer (CRPC). Newer therapeutic agents are needed for treating these CRPC patients that are unresponsive to androgen deprivation and/or chemotherapy. The histone deacetylase (HDAC) family of enzymes limits the expression of genomic regions by improving binding between histones and the DNA backbone. Modulating the role of HDAC enzymes can alter the cell's regulation of proto-oncogenes and tumor suppressor genes, thereby regulating potential neoplastic proliferation. As a result, histone deacetylase inhibitors (HDACi) are now being evaluated for CRPC or chemotherapy-resistant prostate cancer due to their effects on the expression of the androgen receptor gene. In this paper, we review the molecular mechanism and functional target molecules of different HDACi as applicable to CRPC as well as describe recent and current clinical trials involving HDACi in prostate cancer. To date, four HDAC classes comprising 18 isoenzymes have been identified. Recent clinical trials of vorinostat, romidepsin, and panobinostat have provided cautious optimism towards improved outcomes using these novel therapeutic agents for CPRC patients. Nevertheless, no phase III trial has been conducted to cement one of these drugs as an adjunct to androgen-deprivation therapy. Consequently, further investigation is necessary to delineate the benefits and drawbacks of these medications.

Original languageEnglish (US)
Pages (from-to)388-395
Number of pages8
JournalTherapeutic Advances in Urology
Volume7
Issue number6
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Histone Deacetylase Inhibitors
Castration
Prostatic Neoplasms
Clinical Trials
Histone Deacetylases
Androgens
Therapeutics
Drug Therapy
Proto-Oncogenes
Androgen Receptors
Proxy
Enzymes
Tumor Suppressor Genes
Histones
Isoenzymes
DNA

Keywords

  • castration-resistant prostate cancer
  • clinical trials
  • histone deacetylase inhibitors

ASJC Scopus subject areas

  • Urology

Cite this

Histone deacetylase inhibitors in castration-resistant prostate cancer : Molecular mechanism of action and recent clinical trials. / Kaushik, Dharam; Vashistha, Vishal; Isharwal, Sudhir; Sediqe, Soud A.; Lin, Ming Fong.

In: Therapeutic Advances in Urology, Vol. 7, No. 6, 01.01.2015, p. 388-395.

Research output: Contribution to journalReview article

@article{9854e7a5ed994bb48e54e60a131ac98f,
title = "Histone deacetylase inhibitors in castration-resistant prostate cancer: Molecular mechanism of action and recent clinical trials",
abstract = "Historically, androgen-deprivation therapy has been the cornerstone for treatment of metastatic prostate cancer. Unfortunately, nearly majority patients with prostate cancer transition to the refractory state of castration-resistant prostate cancer (CRPC). Newer therapeutic agents are needed for treating these CRPC patients that are unresponsive to androgen deprivation and/or chemotherapy. The histone deacetylase (HDAC) family of enzymes limits the expression of genomic regions by improving binding between histones and the DNA backbone. Modulating the role of HDAC enzymes can alter the cell's regulation of proto-oncogenes and tumor suppressor genes, thereby regulating potential neoplastic proliferation. As a result, histone deacetylase inhibitors (HDACi) are now being evaluated for CRPC or chemotherapy-resistant prostate cancer due to their effects on the expression of the androgen receptor gene. In this paper, we review the molecular mechanism and functional target molecules of different HDACi as applicable to CRPC as well as describe recent and current clinical trials involving HDACi in prostate cancer. To date, four HDAC classes comprising 18 isoenzymes have been identified. Recent clinical trials of vorinostat, romidepsin, and panobinostat have provided cautious optimism towards improved outcomes using these novel therapeutic agents for CPRC patients. Nevertheless, no phase III trial has been conducted to cement one of these drugs as an adjunct to androgen-deprivation therapy. Consequently, further investigation is necessary to delineate the benefits and drawbacks of these medications.",
keywords = "castration-resistant prostate cancer, clinical trials, histone deacetylase inhibitors",
author = "Dharam Kaushik and Vishal Vashistha and Sudhir Isharwal and Sediqe, {Soud A.} and Lin, {Ming Fong}",
year = "2015",
month = "1",
day = "1",
doi = "10.1177/1756287215597637",
language = "English (US)",
volume = "7",
pages = "388--395",
journal = "Therapeutic Advances in Urology",
issn = "1756-2872",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Histone deacetylase inhibitors in castration-resistant prostate cancer

T2 - Molecular mechanism of action and recent clinical trials

AU - Kaushik, Dharam

AU - Vashistha, Vishal

AU - Isharwal, Sudhir

AU - Sediqe, Soud A.

AU - Lin, Ming Fong

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Historically, androgen-deprivation therapy has been the cornerstone for treatment of metastatic prostate cancer. Unfortunately, nearly majority patients with prostate cancer transition to the refractory state of castration-resistant prostate cancer (CRPC). Newer therapeutic agents are needed for treating these CRPC patients that are unresponsive to androgen deprivation and/or chemotherapy. The histone deacetylase (HDAC) family of enzymes limits the expression of genomic regions by improving binding between histones and the DNA backbone. Modulating the role of HDAC enzymes can alter the cell's regulation of proto-oncogenes and tumor suppressor genes, thereby regulating potential neoplastic proliferation. As a result, histone deacetylase inhibitors (HDACi) are now being evaluated for CRPC or chemotherapy-resistant prostate cancer due to their effects on the expression of the androgen receptor gene. In this paper, we review the molecular mechanism and functional target molecules of different HDACi as applicable to CRPC as well as describe recent and current clinical trials involving HDACi in prostate cancer. To date, four HDAC classes comprising 18 isoenzymes have been identified. Recent clinical trials of vorinostat, romidepsin, and panobinostat have provided cautious optimism towards improved outcomes using these novel therapeutic agents for CPRC patients. Nevertheless, no phase III trial has been conducted to cement one of these drugs as an adjunct to androgen-deprivation therapy. Consequently, further investigation is necessary to delineate the benefits and drawbacks of these medications.

AB - Historically, androgen-deprivation therapy has been the cornerstone for treatment of metastatic prostate cancer. Unfortunately, nearly majority patients with prostate cancer transition to the refractory state of castration-resistant prostate cancer (CRPC). Newer therapeutic agents are needed for treating these CRPC patients that are unresponsive to androgen deprivation and/or chemotherapy. The histone deacetylase (HDAC) family of enzymes limits the expression of genomic regions by improving binding between histones and the DNA backbone. Modulating the role of HDAC enzymes can alter the cell's regulation of proto-oncogenes and tumor suppressor genes, thereby regulating potential neoplastic proliferation. As a result, histone deacetylase inhibitors (HDACi) are now being evaluated for CRPC or chemotherapy-resistant prostate cancer due to their effects on the expression of the androgen receptor gene. In this paper, we review the molecular mechanism and functional target molecules of different HDACi as applicable to CRPC as well as describe recent and current clinical trials involving HDACi in prostate cancer. To date, four HDAC classes comprising 18 isoenzymes have been identified. Recent clinical trials of vorinostat, romidepsin, and panobinostat have provided cautious optimism towards improved outcomes using these novel therapeutic agents for CPRC patients. Nevertheless, no phase III trial has been conducted to cement one of these drugs as an adjunct to androgen-deprivation therapy. Consequently, further investigation is necessary to delineate the benefits and drawbacks of these medications.

KW - castration-resistant prostate cancer

KW - clinical trials

KW - histone deacetylase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84947276559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947276559&partnerID=8YFLogxK

U2 - 10.1177/1756287215597637

DO - 10.1177/1756287215597637

M3 - Review article

AN - SCOPUS:84947276559

VL - 7

SP - 388

EP - 395

JO - Therapeutic Advances in Urology

JF - Therapeutic Advances in Urology

SN - 1756-2872

IS - 6

ER -